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CONTROLLING DENDRITIC CELL FUNCTION BY TARGETING IRON-MODULATING 
PROTEINS IDENTIFIED THROUGH TRANSCRIPTIONAL ANALYSIS 
 
Anna Selene Roessing, M.S. 
University of Pittsburgh, 2018 
Dendritic cells (DC) are key orchestrators of the body’s immune responses. DC control T cell 
proliferation and differentiation while displaying cognate antigen (Ag) to Ag-specific T cells.  
DC cytokine secretion is central to the differentiation of T cells into distinct, functional subsets. 
Stimulation with bacteria-derived molecules such as lipopolysaccharide (LPS) through Toll-like 
receptor 4 (TLR4) leads to interleukin-12 (IL-12) production by DC and supports T helper type 1 
(Th1) generation in interacting cluster of differentiation 4 (CD4+) T cells. Fungal interactions 
with the Dectin-1 receptor yields IL-6, IL-23, and IL-1β production by DC to mediate Th17 cell 
polarization. DC, especially those exposed to IL-33, support the generation of IL-5- and IL-13- 
secreting Th2 cells. However, there are no identified DC-produced cytokines which have been 
shown to directly underlie Th2 polarization. 
The aim of this project was to identify novel genes and signaling pathways by which 
CD4+ T cell polarization is directed following DC TLR4/ST2 (IL1RL1) ligation. Our 
preliminary data demonstrated that IL-33 and LPS stimulate the expression of several iron- 
modulating proteins in DC, such as lipocalin 2 (Lcn2), hemoglobin-α, and cytochrome b5 
reductase 3 (Cyb5R3), which act as a previously unappreciated DC nitric oxide (NO) 
sequestration system. Given these findings, we hypothesized that TLR4/ST2 ligation on DC 
causes  expression  of  iron-modulating  proteins  which  sequester  NO.  We found that while 
TLR4/ST2 receptor ligation on DC induces a NO sequestration system in DC, it involves the 
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expression of hemoglobin-α and potentially other redundant reductase proteins, but not Cyb5R3. 
Instead, we determined that Cyb5R3 acts as a regulator of DC stimulatory capacity toward CD4+ 
T cells. Specifically, Cyb5R3 functions as a negative regulator of glycolysis. In Cyb5R3- 
expressing cells, unstimulated and IL-33-stimulated cells favor oxidative phosphorylation 
(OXPHOS) while LPS stimulation leads a shift towards glycolysis. Finally, Cyb5R3-deficient 
DC are both more inflammatory and more stimulatory, producing greater amounts of IL-12 and 
expressing more stimulatory surface markers, ultimately leading to Th1 cell polarization of naïve 
T cells, especially upon DC stimulation with LPS. 
vi  
 
 
ACKNOWLEDGEMENTS 
 
I would first like to thank my P.I., Hēth Turnquist, for giving me the opportunity to study and work 
 
as part of his laboratory. 
 
I would also like to sincerely thank my thesis committee members for supporting my research 
and believing in me as a scientist. 
Finally, I would like to thank my friends and family, for their unwavering love and support 
through one of the hardest times of my life. Your compassion and faith have meant the world to me, 
and I never would have made it this far without it. This thesis is dedicated to you. All min kjærlighet. 
vii  
 
 
 
 
 
TABLE OF CONTENTS 
1.0 INTRODUCTION .............................................................................................................. 1 
1.1 DENDRITIC CELL MATURATION AND ACTIVATION ................................. 1 
1.2 CD4+ T CELL POLARIZATION AND DIFFERENTIATION............................. 2 
1.3 EXOGENOUS AND ENDOGENOUS MOLECULES THAT SHAPE DC 
CAPACITY FOR TH CELL POLARIZATION..................................................... 4 
1.4 NITRIC OXIDE SEQUESTRATION PATHWAY ............................................... 6 
2.0 MATERIALS AND METHODS ........................................................................................ 9 
2.1 MICROARRAY AND DATA ANALYSIS ........................................................... 9 
2.2 WESTERN BLOTTING ....................................................................................... 10 
2.3 MIXED LYMPHOCYTE REACTIONS AND ELISAS ...................................... 10 
2.4 DENDRITIC CELL PHENOTYPING ................................................................. 11 
3.0 RESULTS AND ANALYSIS ........................................................................................... 12 
3.1 MICROARRAY ANALYSIS OF STIMULATED DENDRITIC CELLS FOR 
DIFFERENTIAL GENE EXPRESSION .............................................................. 12 
3.2 IL-33 INDUCTION OF INOS YIELDS LOWER NITRIC OXIDE SECRETION 
FROM DENDRITIC CELLS COMPARED TO LPS-STIMULATED 
DENDRITIC CELLS ............................................................................................ 15 
 
viii 
3.3 INCREASED NITRIC OXIDE LEVELS MAY LIMIT THE CAPACITY OF 
DENDRITIC CELLS FOR TH2 POLARIZATION ............................................. 17 
3.4 MOUSE MODEL FOR THE EFFECTIVE KNOCKDOWN OF CYB5R3 
EXPRESSION IN VITRO AND IN VIVO .......................................................... 18 
3.5 CYB5R3 FUNCTIONS AS A REGULATOR OF DENDRITIC CELL 
STIMULATORY CAPACITY ............................................................................. 20 
3.6 CYB5R3 DOES NOT HAVE A ROLE IN THE NITRIC OXIDE 
SEQUESTRATION PATHWAY OF DENDRITIC CELLS ................................. 21 
3.7 DELETION OF CYB5R3 FROM CD11C+ BMDC SHIFTS METABOLISM 
TOWARDS GLYCOLYSIS ................................................................................. 22 
3.8 CD11C+ CYB5R3-DEFICIENT DENDRITIC CELLS SHOW AN INCREASE 
IN STIMULATORY MARKERS AND INFLAMMATORY CYTOKINES ...... 24 
4.0 DISCUSSION ................................................................................................................... 26 
4.1 TLR4/ST2 RECEPTOR LIGATION ON DC INDUCES A NITRIC OXIDE 
SEQUESTRATION SYSTEM THAT DOES NOT RELY ON CYB5R3 ........... 26 
4.2 CYB5R3 ACTS AS A REGULATOR OF DENDRITIC CELL STIMULATORY 
CAPACITY TOWARDS CD4+ T CELLS ........................................................... 27 
4.3 CYB5R3 IS A NEGATIVE REGULATOR OF GLYCOLYSIS AND 
DENDRITIC CELLS SHOW A SHIFTED METABOLIC PROFILE IN ITS 
ABSENCE ............................................................................................................ 28 
APPENDIX ....................................................................................................................... 30 
BIBLIOGRAPHY ............................................................................................................. 32 
ix  
 
 
 
 
LIST OF FIGURES 
 
 
 
 
Figure 1. Endothelial Cell Expression of Hemoglobin-α and Cyb5R3 Facilitates NO 
Scavenging ..................................................................................................................................... 6 
 
Figure 2.  Schematic of NO Sequestration Proteins and Activity ............................................. 8 
 
Figure 3.  Microarray Analysis and Western Blotting of Stimulated Dendritic Cells .......... 12 
 
Figure 4. IL-33 Induces Lower NO Secretion from iNOS Compared to LPS ...................... 15 
 
Figure 5.  Increased NO Levels may Limit DC Th2 Polarization Capacity .......................... 17 
 
Figure 6.  Mouse Model is Effective for Knockdown of Cyb5R3 Expression ........................ 18 
 
Figure 7.  Cyb5R3 regulates DC Stimulatory Capacity .......................................................... 20 
 
Figure 8.  Cyb5R3 does not have a role in the NO Sequestration Pathway ............................ 21 
 
Figure 9.  Deletion of Cyb5R3 from CD11c+ BMDC Causes a Metabolic Shift ................... 22 
 
Figure 10. CD11c+ Cyb5R3-Deficient DC show an Increase in Stimulatory Markers and 
Inflammatory Cytokines ............................................................................................................ 24 
x  
 
 
 
 
 
LIST OF TABLES 
 
 
 
 
Table 1. Abbreviations ............................................................................................................... 30 
1  
 
 
 
1.0 INTRODUCTION 
 
 
 
1.1 DENDRITIC CELL MATURATION AND ACTIVATION 
 
 
First identified by Ralph Steinman in 1973 [1], DC are hematopoietic cells that are specialized 
for antigen presentation and have roles in both innate and adaptive immune responses. They 
express various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid- 
inducible gene 1 (RIG-1)-like receptors (RLRs), and C-type lectins [2]. PRRs bind molecular 
motifs that are characteristic of particular pathogens or that are associated with cellular damage. 
Ligation of PRRs induces the maturation of DC, initiating signaling pathways that lead to 
cellular activation and marked changes in gene expression and metabolism that direct the 
expression of cytokines, co-receptors, chemokines, and other functional molecules [3]. The 
change from resting DC to activated DC involves a transition in which the cells become more 
dendritic in appearance and more secretory, allowing them to become better at interaction with 
other cells [4]. DC activated by PRRs drive the activation of naïve T cells toward antigen- 
specific T cells. 
Metabolic studies in DC following PRR ligation have shown how their biochemical 
activity also shapes their maturation and functionality following a shift from resting state to 
activation. Changes in DC appearance are accompanied by changes in cellular metabolism that 
are necessary and essential to activation [2]. As an example, DC activation in response to TLR 
ligation leads to an increase in glucose consumption and lactic acid production due to a rapid 
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increase in glycolytic flux that occurs within minutes of stimulation by TLR agonists [5]. This 
glycolytic flux fulfills the need for citrate in activated DC. In DC, the export of citrate from 
mitochondria into the cytoplasm is especially important for fatty acid synthesis. Fatty acid 
synthesis is linked to the requirement of activated DC to increase the size of their endoplasmic 
reticulum (ER) and Golgi apparatus. These organelles are integral in protein synthesis and 
secretion, producing proteins that are essential to DC activation and cellular interaction [5, 6]. In 
this way, DC activation and maturation regulate antigen capturing, processing and presentation, 
and the expression of costimulatory molecules [7]. 
 
 
 
1.2 CD4+ T CELL POLARIZATION AND DIFFERENTIATION 
 
 
Once DC are matured and activated, they are able to display the peptide antigens they have 
generated from processed extracellular proteins on their surface through their major 
histocompatibility complex (MHC) receptors for potentially responsive T cells. These peptides 
are presented in major histocompatibility complex class II (MHCII) receptors and allow for 
peptide inspection through the T cell receptor (TCR) expressed by interacting T cells. At the 
immune synapse, adhesion molecules allow DC and T cells to come into contact, sequentially 
triggering TCR stimulation by the MHC-peptide complexes if the TCR is cognate to the 
complexes [8, 9]. In order for a naïve T cell to polarize towards a CD4+ T cell, the TCR must 
engage with peptide presented on MHCII as well as direct binding of the CD4 surface marker to 
the MHC [10]. This CD4-MHCII interaction strengthens the signal between the TCR and the 
peptide [9]. Co-stimulation occurs through engagement of T cell-expressed CD28 by B7 
molecules on DC, amplifying the signaling initiated by the TCR up to 100-fold. Depending on 
the level of co-stimulation and the amount of peptide presented, between 6 and 30 hours of TCR 
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stimulation is required for a naïve T cell to become committed to a T helper cell subset [11]. 
After a cell has committed to a subset and begins division, T cells proliferate rapidly in response 
to IL-2, which is produced in either a paracrine or autocrine manner by activated T cells. These 
CD4+ T cells are now fully functional immune cells of a specific Th subset. 
CD4+ T cells play a critical role in the immune response. They have the capacity to help 
B cells produce antibodies, to induce macrophages to develop microbicidal activity, to recruit 
other cells to sites of infection (such as neutrophils, eosinophils, and basophils) and to produce 
cytokines important for adaptive immune responses [12]. To fulfill these functions, CD4+ T cells 
differentiate to become Th1, Th2, Th9, Th17, T regulatory (Treg), and T follicular helper (Tfh) 
cells, each with a unique cytokine profile that mediates their effector functions. In order for 
differentiation to occur, activation of a set of cytokine signaling pathways and lineage-specific 
transcription factors is required [13]. For the purposes of relevance to this discussion, the scope 
will be limited to Th1 and Th2 differentiation. 
IL-12 and interferon-γ (IFN-γ) are the critical cytokines to initiate the downstream 
signaling cascade for Th1 cell differentiation [14]. IL-12 is secreted in large amounts by DC after 
their activation through their PRRs [15]. The master regulator for Th1 differentiation, T-box 
transcription factor (T-bet), is crucial, not only for its ability to activate the set of genes to 
promote Th1, but also for its suppression of the development of opposing cell lineages [16, 17]. 
T-bet significantly enhances the production of IFN-γ and plays an important role in suppressing 
Th2 differentiation [17]. T-bet suppresses the development of Th2 cells through the inhibition of 
the IL-4 gene and the Th2 master regulator GATA-binding protein 3 (GATA3) [18, 19]. 
IL-4 and IL-2 are the critical cytokines for initiating Th2 differentiation. The major 
transcription factor involved in Th2 differentiation is the IL-4-induced signal transducer and 
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activator of transcription 6 (STAT6), which is responsible for upregulating the expression of the 
master regulator GATA3 [20, 21]. While much progress has been made in the field of T cell 
biology, the exact pathway underlying DC polarization of Th2 cells has yet to be clarified. 
Therefore, three mechanisms of GATA3 involvement in Th2 differentiation have been theorized. 
These include 1.) enhanced Th2 cytokine production, 2.) selective proliferation through 
recruitment of growth factor independent-1 (Gfi-1), and 3.) inhibition of Th1 differentiation [22]. 
Further research has also suggested the involvement of several other transcriptional factors 
activated downstream, such as STAT3, STAT5, and suppressor of cytokine signaling-1 (SOCS- 
1) as well as several cytokines, including IL-2 and IL-6 [23- 26]. 
 
 
 
 
1.3 EXOGENOUS AND ENDOGENOUS MOLECULES THAT SHAPE DC 
CAPACITY FOR TH CELL POLARIZATION 
 
 
As previously addressed in section 1.1, DC express various PRRs that interact with molecular 
motifs of cellular and microorganismal origin. The molecules these receptors interact with 
greatly affect how CD4+ T cells will become polarized. Pathogen-associated molecular patterns 
(PAMPs) are exogenous molecules derived from microorganisms that are recognized by the 
PRRs of DC as well as many epithelial cells. In contrast, damage-associated molecular patterns 
(DAMPs) are endogenous, cell-derived molecules that initiate and perpetuate immunity in 
response to trauma and tissue damage [27]. 
Bacterial and viral motifs are the most common drivers of Th1 responses [28]. Surface 
membrane-expressed TLRs such as TLR4 and TLR5 recognize PAMPs such as LPS and 
bacterial flagellin. However, TLR3, TLR7, and TLR9, expressed on endosomal compartments 
within DC, interact with viral and bacterial nucleic acid PAMPs, such as double-stranded RNA, 
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single-stranded RNA, and unmethylated double-stranded DNA, respectively [28]. In contrast, 
Th2 responses have been linked to helminth molecules as well as cell damage motifs. For 
instance, receptors such as the mannose receptor on DC bind to the PAMP Schistosoma mansoni 
soluble egg antigen (SEA) [28]. Similarly, ST2 binds to the DAMP IL-33, following its release 
from injured cells. IL-33, and similar motifs released from cells that are normally localized to a 
cellular compartment under homeostatic conditions, are sometimes referred to as alarmins [29]. 
IL-33, a member of the IL-1 superfamily of cytokines, is expressed by stromal cells, such 
as epithelial and endothelial cells, and upregulated following pro-inflammatory stimulation. IL- 
33 can function as both a traditional cytokine and as a regulatory factor of gene transcription. It 
mediates its biological effects through receptor interaction with ST2 and IL-1 receptor accessory 
protein (IL-1RAcP), both of which are widely expressed, particularly by innate immune cells. IL-
33 has been shown to strongly induce Th2 polarization and can promote the pathogenesis of Th2-
related diseases such as asthma and anaphylaxis. However, IL-33 has also shown various 
protective effects in cardiovascular diseases such as atherosclerosis, obesity, and type 2 diabetes 
[30]. Interestingly, both the LPS receptor TLR4 and IL-33 share a common signaling pathway. 
Under normal physiological conditions, upon activation of a TLR or IL-1R superfamily member, 
the transmembrane receptor’s Toll/Interleukin-1 receptor (TIR) domain dimerizes with the TIR 
domain of the cytosolic adaptor molecules. This triggers the adaptor proteins myeloid 
differentiation primary response 88 (MyD88) and IL-1R-associated kinase (IRAK) to activate 
downstream mitogen-activated protein kinase (MAPK)-kinases through tumor necrosis factor 
receptor-associated factor 6 (TRAF6) signaling. In turn, this leads to the activation of activator 
protein 1 (AP-1) through c-Jun N-terminal kinases (JNKs). TRAF6 also activates the inhibitor of 
the nuclear factor-κB (NF-κB) kinase complex, allowing access to the active form of NF-κB 
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[31]. Thus, the effects of IL-33 are either pro- or anti-inflammatory, leading to Th1 or Th2 
polarization, depending on the PAMPs and DAMPs present in the environment and the 
interacting PRRs on DC. 
 
 
 
1.4 NITRIC OXIDE SEQUESTRATION PATHWAY 
 
 
 
Figure 1. Endothelial Cell Expression of Hemoglobin-α and Cyb5R3 Facilitates NO Scavenging. In endothelial 
cells, NO diffusion out of the cell into the myoendothelial junction is controlled by the iron redox state of 
hemoglobin-α, which is modulated by Cyb5R3. When the iron group bound to hemoglobin-α globin is reduced to 
Fe2+, NO is sequestered. However, when the iron group bound to hemoglobin-α is oxidized to Fe3+, NO diffusion is 
permitted [32]. This figure illustrates a similarly functioning pathway with fewer proteins than our research has 
identified in DC. 
 
 
As the NO scavenging pathway to be discussed in this thesis has yet to be described in immune 
cells, this explanation will pertain to the relevant similarities in protein expression and function 
published in endothelial cells (EC). 
The hemoglobin-α pathway of NO sequestration was first identified in 2012 as a 
 
regulator of NO on vascular activity in arterial EC (Figure 1) [33]. While the sequestration 
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mechanism itself is due to the redox state of the iron group bound to hemoglobin-α, there are 
upstream proteins involved which must first be activated in order for this downstream NO 
sequestration to be achieved [34]. 
The protein acting as the initiator of this pathway in EC, and potentially in immune cells, 
is Lcn2 (Figure 2). Lcn2 is a secreted protein that sequesters iron from bacterial siderophores and 
has been shown to act as a regulator of human hematopoiesis [35, 36]. In this pathway, Lcn2 
introduces ferric (Fe3+) iron to the system, which signals to aminolaevulinic acid synthase 1 
(Alas1). Alas1 is the ubiquitous, rate-limiting enzyme, formed by the condensation of glycine 
and succinyl-CoA. It has the important housekeeping function of providing heme to non- 
erythroid tissues [37]. Once it is signaled by Lcn2, Alas1 initiates the production of hemoglobin- 
α. Hemoglobin-α allows the Fe3+ introduced by Lcn2 to become a bound iron group (Figure 2). 
Hemoglobin-α is comprised of two α and two β globin subunits in a heterocyclic ring of four 
pyrrole molecules which are known as a porphyrin [38]. The hemoglobin-α tetramer is able to 
interact with carbon dioxide as well as carbon monoxide [39]. In this pathway, hemoglobin-α is 
able to sequester NO following the reduction of its Fe3+ group to ferrous (Fe2+) iron. This 
sequestration only occurs following the redox activity of Cyb5R3 (Figure 2). Cyb5R3 is a 
flavoprotein enzyme involved in the transfer of electrons from the physiological electron donor 
nicotinamide adenine dinucleotide (NADH) through its flavin adenine dinucleotide (FAD) 
domain. It is also critically important in many oxidation and reduction reactions [40]. For the NO 
sequestration pathway in EC, Cyb5R3 reduces ferric iron once it is bound by hemoglobin-α [32- 
34, 41]. This creates a free electron on the ferrous iron group bound to hemoglobin-α, which is 
more energetically favorable than ferric iron (which lacks a free electron). The free electron 
allows for iron nitrosylation to occur as the ferrous iron coupled to hemoglobin-α sequesters NO, 
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preventing its diffusion from the cell [33]. Alternatively, the absence of either hemoglobin-α, for 
the iron group to be bound, or Cyb5R3, for the ferric iron group to be reduced to ferrous iron, 
permits free diffusion of NO from the EC. 
 
 
Figure 2. Schematic of NO Sequestration Proteins and Activity. As the pathway has been described in vascular 
endothelial cells, Lcn2 sequesters iron from bacterial siderophores to bring ferric (Fe3+) iron to the hemoglobin 
pathway. Upon the introduction of ferric iron, the enzyme Alas1 initiates production of hemoglobin-a, the protein 
which accepts the iron. Once hemoglobin-a accepts ferric iron, it is able to be reduced by Cyb5R3 to ferrous (Fe2+) 
iron. It is ferrous iron that has a free electron, allowing iron nitrosylation which functions as a NO sink. 
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2.0 MATERIALS AND METHODS 
 
 
 
2.1 MICROARRAY AND DATA ANALYSIS 
 
 
C57BL/6 mice were used to generate bone-marrow derived DC (BMDC) through a seven-day 
culture with IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF), plated at 
4x106 cells per plate. Fresh complete RPMI 1640 media and cytokines were added on days two, 
four, and six of BMDC culture. On day seven, fifteen C57BL/6 samples with five replicates per 
treatment were harvested six hours following exposure to media alone, E. coli-derived LPS (100 
ng/ml), or rIL-33 (20 ng/ml) and used to complete an Illumina BeadArray microarray 
(MouseWG-6_Version2), which probed for 45,2000 transcripts. The data were then analyzed 
with GeneSpring (version 14.8). Raw data were baseline transformed to the mean of all samples 
and averaged over replicates. Gene expression was filtered by percentile (30th-100th). A One-way 
ANOVA with Tukey HSD post hoc, asymptotic p-value, and Benjamini-Hochberg FDR 
correction was used for treatment comparison between gene lists. 
All mice were bred and maintained in accordance with the University of Pittsburgh’s 
Department of Laboratory Animal Resources guidelines and all animal experiments were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee. 
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2.2 WESTERN BLOTTING 
 
 
C57BL/6 BMDC (generated as in section 2.1) or Rosa26ERT2 x Cyb5R3Fl/Fl whole splenic 
protein (from mice which received five days of intraperitoneal tamoxifen injections) was left 
untreated or stimulated approximately eighteen hours with media alone, LPS (100 ng/ml), or rIL- 
33 (20 ng/ml). Samples were then collected by centrifugation at 1500rpm for five minutes, lysed 
using RIPA buffer, pelleted by centrifugation at 1300rpm for twenty minutes at 4°C, and protein 
quantified by BCA assay. 
Proteins were run on 4-12% Tris-Glycine Mini Gels in an XCell SureLock™ Mini-Cell 
box at 125V for ninety minutes. The blots were carefully transferred to a PVDF membrane using 
the XCell II™ Blot Module at 25V for two hours. Membranes were incubated at room 
temperature in 5% fetal bovine serum (FBS) for one hour to block background and rocked 
overnight in a cold room with anti-conjugated protein prepared in 5% FBS. The following day, 
secondary antibodies were added following washes with tris-buffered saline/Tween 20 (TBST) 
and incubated for one hour. Detection reagents were added following washes with TBST and 
incubated for five minutes. Proteins were then detected using film. 
 
 
 
2.3 MIXED LYMPHOCYTE REACTIONS AND ELISAS 
 
 
C57BL/6 or Rosa26ERT2 x Cyb5R3Fl/Fl mice were used to generate BMDC through a seven-day 
culture as outlined in section 2.1. When Rosa26ERT2 x Cyb5R3Fl/Fl BMDC were used, 4- 
hydroxytamoxifen was added to half of the plates, along with fresh media and cytokines, on days 
two, four, and six of BMDC culture. On day seven, cells were harvested and CD11c bead 
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purified to isolate DC. DC were either left untreated or stimulated for eighteen hours with LPS 
(100 ng/ml), or rIL-33 (20 ng/ml) in 24-well plates. The following day, DC were plated in a five- 
day mixed lymphocyte reaction (MLR) with untouched CD4 bead-purified T cells isolated from 
Balb/c splenocytes. 
CD4+ T cell cytokine production was measured by Mouse IL-5 ELISA MAX™ and 
Mouse IFN-γ ELISA MAX™ enzyme-linked immunosorbent assays (ELISAs) from the 
supernatants following protein quantification. 
 
 
 
2.4 DENDRITIC CELL PHENOTYPING 
 
 
Rosa26ERT2 x Cyb5R3Fl/Fl mice were used to generate BMDC through a seven-day culture as 
outlined in section 2.1. 4- hydroxytamoxifen was added to half of the plates, along with fresh 
media and cytokines, on days two, four, and six of BMDC culture. On day seven, cells were 
harvested and CD11c bead purified to isolate DC. DC were either left untreated or stimulated for 
eighteen hours with LPS (100 ng/ml), or rIL-33 (20 ng/ml) in 24-well plates. 
The following day, GolgiPlug™ Protein Transport Inhibitor (containing Brefeldin A) was 
added to the cells for five hours. DC were collected and stained for the cell surface markers 
CD11b (V450 (1:300)), CD11c (PE/Cy7 (1:200)), CD80 (APC, (1:300)). CD86 (PerCPCy5.5 
(1:300)), MHCII FITC (1:100)), and the cytokine IL-12p40 (PE (1:50) intracellular). Samples 
were run on a BD LSR II™ Flow Cytometer and analyzed using FlowJo® version 10. 
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3.0 RESULTS AND ANALYSIS 
 
 
 
3.1 MICROARRAY ANALYSIS OF STIMULATED DENDRITIC CELLS FOR 
DIFFERENTIAL GENE EXPRESSION 
Figure 3. Microarray Analysis and Western Blotting of Stimulated Dendritic Cells. A. PCA analysis of 
C57BL/6 BMDC samples following six hours of stimulation in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). 
n=5 samples per treatment group; 15 total. Data is representative of one experiment. Green= Untreated, Red= rIL- 
33, Aqua= LPS B. Top fifty genes upregulated in fold-change expression analysis of rIL-33 versus Untreated. Genes 
are listed in alphabetical order from left to right. C. Western blot images of C57BL/6 BMDC samples following 
eighteen hours of stimulation in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). Anti-mouse antibodies were 
used to probe for hemoglobin-a, Lcn2, and the GAPDH loading control. Anti-goat antibody was used to probe for 
Cyb5R3. 
A 
C 
B 
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As previously mentioned in section 1.2, there are no DC-produced cytokines identified which 
have been shown to directly underlie Th2 polarization of CD4+ T cells. In our attempts to 
elucidate this, we have shown that overnight stimulation of C57BL/6 BMDC in media alone, in 
LPS, or in rIL-33, with subsequent co-culture in an allogeneic MLR yields Th2 polarization by 
IL-33-stimulated DC and Th1 polarization by LPS-stimulated DC [42]. This lead to the 
observation that, while IL-33- and LPS-stimulated DC are polarizing CD4+ T cells toward 
different subsets, they are utilizing the same MyD88 signaling pathway [43]. Thus, we began 
investigating why TLR4 and ST2 ligation both activate the same MyD88-dependent pathway but 
generate different functional outcomes through the identification of novel genes. 
We began to address this question by looking at C57BL/6 BMDC samples that were 
harvested six hours following exposure to media alone, LPS, or rIL-33 and completing an 
Illumina microarray which was then analyzed with GeneSpring. After the normalization and 
averaging of the data, a principle component analysis (PCA) was used to determine the similarity 
of the replicate sets. We established that the three treatment groups appeared to represent distinct 
gene subsets (Figure 3A). Following the PCA, a fold-change expression analysis was completed 
between the IL-33-stimulated DC and the DC in media alone, specifically looking at those genes 
upregulated in the IL-33-stimulated DC (Figure 3B). Using Ingenuity® Pathway Analysis, the 
genes with the highest expression above baseline in the IL-33-stimulated DC were analyzed for 
function. From this, we came to identify Alas1 and Lcn2 as iron-modulating proteins, both of 
which were found in the NO sequestration pathway involving hemoglobin-α and upregulated by 
IL-33 stimulation of DC. Since this NO sequestration pathway had only been described in 
vascular EC, we verified our gene expression data and searched for other proteins of the 
hemoglobin-α pathway through Western blots of BMDC following eighteen hours of treatment 
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in media alone, LPS, or rIL-33 (Figure 3C). Notably, the expression of Lcn2, hemoglobin-α, and 
Cyb5R3 increase with BMDC stimulation by IL-33 and LPS. This suggested that these stimuli 
are utilizing the same MyD88 signaling pathway in DC to activate these proteins following their 
receptor ligation and may trigger a potential NO sequestration pathway. 
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3.2 IL-33 INDUCTION OF INOS YIELDS LOWER NITRIC OXIDE SECRETION 
FROM DENDRITIC CELLS COMPARED TO LPS-STIMULATED 
DENDRITIC CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. IL-33 Induces Lower NO Secretion from iNOS Compared to LPS. A. mRNA analysis of iNOS 
expression C57BL/6 BMDC samples following three or six hours of stimulation in media alone, LPS (100 ng/ml), or 
rIL-33 (20 ng/ml) as designated. B. Western blot image of C57BL/6 BMDC samples following eighteen hours of 
stimulation in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). Anti-mouse antibodies were used to probe for 
iNOS and the GAPDH loading control. This blot is representative of three completed blots. C. EPR spectra of NO 
secretion from whole C57BL/6 BMDC, Top: Control DC, Middle: LPS-stimulated DC, Bottom: IL-33-stimulated 
DC. D. EPR spectra amplitude quantified. Statistical analysis by Student’s paired t-test, p = 0.029 (control vs LPS), 
p < 0.001 (LPS vs IL-33), Control and LPS, n = 4-6. 
 
 
Following the identification of these upregulated proteins responsible for the hemoglobin-α NO 
sequestration system in vascular EC in our DC, we wanted to evaluate the response of the NO- 
producing, DC protein inducible nitric oxide synthase (iNOS). iNOS is an enzyme stimulated by 
cytokines and bacterial products in a number of cells, including monocytes and macrophages. It 
A C 
  B 
D 
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is one of three isoforms of NOS that are responsible for producing NO in the body [2]. Both the 
messenger RNA (mRNA) and protein levels from a C57BL/6 mouse showed induction of iNOS 
at levels roughly three-fold over the control after incubation with rIL-33. This level of expression 
is lower than that caused by LPS, which was roughly ten-fold over the control (Figure 4A and 
B). Using electron paramagnetic resonance spectroscopy (EPR), we measured the NO secreted 
by the DC following overnight stimulation. Interestingly, IL-33 stimulates a comparable amount 
of NO secretion as DC in media alone when compared to LPS-treated DC (Figure 4C and D). 
Together, this demonstrated that IL-33 induces iNOS mRNA and protein but does not stimulate 
increased NO secretion. This also suggested that stimulation of DC with IL-33 does not lead to 
NO secretion in the canonical iNOS pathway and provided further evidence of an active NO 
sequestration system activated by ST2 ligation. 
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3.3 INCREASED NITRIC OXIDE LEVELS MAY LIMIT THE CAPACITY OF 
DENDRITIC CELLS FOR TH2 POLARIZATION 
 
 
Figure 5. Increased NO Levels may Limit DC Th2 Polarization Capacity. C57BL/6 BMDC were stimulated 
overnight with media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml) for use in an MLR with bead purified CD4+ 
Balb/c T cells with or without the exogenous NO donor DETA. Five days later, cytokine production was measured 
by ELISA. For A. the IL-5 response from CD4+ T cells and B. the IFN- response from CD4+ T cells. Statistical 
analysis by Student’s paired t-test. 
 
 
After understanding the effect of IL-33-stimulation on iNOS and DC NO production, we chose 
to address how the addition of NO impacted IL-33-mediated DC Th2 polarization. Using 
C57BL/6 BMDC, stimulating them for eighteen hours in media alone, with LPS, or with rIL-33, 
and subsequently co-culturing them in an allogeneic MLR with or without the NO donor 
diethylenetriamine (DETA), we measured cytokine production by ELISA five days later for IL-5 
(as a Th2 marker) and IFN-γ (as a Th1 marker). The results indicated that the addition of NO 
dampens the normally robust IL-5 response seen from IL-33-DC-stimulated T cells (Figure 5A). 
Interestingly, the addition of NO had no effect on IFN-γ from LPS-stimulated T cells (Figure 
5B). This demonstrated that increased NO levels may limit the ability of IL-33-stimulated DC to 
mediate Th2 polarization specifically. 
A B 
18  
3.4 MOUSE MODEL FOR THE EFFECTIVE KNOCKDOWN OF CYB5R3 
EXPRESSION IN VITRO AND IN VIVO 
 
 
Figure 6. Mouse Model is Effective for Knockdown of Cyb5R3 Expression. A. Western blot image of 4- 
hydroxytamoxifen treated or untreated Rosa26ERT2 x Cyb5R3Fl/Fl BMDC samples following eighteen hours of 
stimulation in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). Anti-goat antibody was used to probe for 
Cyb5R3 and anti-mouse was used for the GAPDH loading control. B. Densitometry analysis for Cyb5R3 expression 
as a fold change ratio normalized to GAPDH. C. Western blot image of five-day tamoxifen treated or untreated 
Rosa26ERT2 x Cyb5R3Fl/Fl splenocytes following eighteen hours of stimulation in media alone, LPS (100 ng/ml), or 
rIL-33 (20 ng/ml). Anti-goat antibody was used to probe for Cyb5R3. D. qRT-PCR analysis of CD11c bead purified 
Rosa26ERT2 x Cyb5R3Fl/Fl BMDC for Cyb5R3 expression. Error expressed as STDEV. 
 
 
Once it was established that the proteins responsible for the hemoglobin-α NO sequestration 
pathway were expressed in our DC and the differential effects of IL-33 and LPS stimulation on 
DC NO secretion and DC function were understood, we realized that in order to best study the 
pathway, the proteins must be studied individually. Cyb5R3 was chosen as the first protein in the 
A B 
C D 
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NO sequestration pathway to evaluate due to its reductase activity, which is vitally important in 
the pathway (see section 1.3). To target this protein, our collaborator, Dr. Adam Straub of the 
University of Pittsburgh Vascular Medicine Institute developed a B6.129- 
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J x Cyb5R3Fl/Fl (Rosa26ERT2 x Cyb5R3Fl/Fl) mouse colony. 
This model was designed as a Tamoxifen-inducible global knockout of Cyb5R3 in all cells. 
The in vitro efficacy of the model was evaluated by harvesting Rosa26ERT2 x Cyb5R3Fl/Fl 
 
BMDC, stimulating them overnight in media alone, LPS, or rIL-33, and culturing them in the 
presence or absence of 4-hydroxytamoxifen to evaluate expression knockdown. Regardless of  
the presence or absence of LPS or IL-33 DC stimulation, there was no induction of Cyb5R3 
expression in the DC treated with 4-hydroxytamoxifen (Figure 6A). This was also evident when 
quantified as a fold change ratio over glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Figure 6B). 
Similarly, to evaluate the in vivo efficacy, whole spleens were harvested from untreated 
Rosa26ERT2 x Cyb5R3Fl/Fl mice and Rosa26ERT2 x Cyb5R3Fl/Fl mice that were treated for five 
days with tamoxifen for a whole splenocyte western blot. This illustrated that there is  
knockdown of Cyb5R3 protein when compared to tamoxifen-untreated spleens (Figure 6C). 
Splenocytes were also harvested for CD11c purification for quantitative real-time polymerase 
chain reaction (qRT-PCR) analysis to evaluate expression-level knockdown of Cyb5R3 (Figure 
6D). These results demonstrated that there was a significant decrease in the expression of 
Cyb5R3 following tamoxifen treatment in vivo when compared to the control. Together, these 
results provided evidence that these mice were useful tools for further in vitro and in vivo studies 
involving Cyb5R3. 
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3.5 CYB5R3 FUNCTIONS AS A REGULATOR OF DENDRITIC CELL 
STIMULATORY CAPACITY 
 
 
 
 
 
Figure 7. Cyb5R3 regulates DC Stimulatory Capacity. 4-hydroxytamoxifen treated or untreated Rosa26ERT2 x 
Cyb5R3Fl/Fl BMDC were stimulated overnight with media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml) for use in an 
MLR with bead purified CD4+ Balb/c T cells. Five days later, cytokine production was measured by ELISA for the 
IL-5 and the IFN-γ response from CD4+ T cells. Statistical analysis by Student’s paired t-test. 
 
 
Once it was established that the Rosa26ERT2 x Cyb5R3Fl/Fl mice were reliable for studies, BMDC 
from these mice were treated with 4-hydroxytamoxifen, harvested, stimulated for eighteen hours 
with LPS or rIL-33, used in an allogeneic MLR, and cytokine production was measured. In the 
presence of Cyb5R3 in DC, production of IL-5 and IFN-γ by T cells following IL-33-DC- or 
LPS-DC-stimulation is dampened, respectively (Figure 7). However, in the absence of Cyb5R3 
in DC, production of IL-5 by T cells following IL-33-DC-stimulation and IFN-γ production by T 
cells following IL-33-DC- and LPS-DC-stimulation is robust (Figure 7). This suggested a 
previously unappreciated role for Cyb5R3 as a regulator of DC stimulatory capacity. 
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3.6 CYB5R3 DOES NOT HAVE A ROLE IN THE NITRIC OXIDE 
SEQUESTRATION PATHWAY OF DENDRITIC CELLS 
 
 
 
 
 
Figure 8. Cyb5R3 does not have a role in the NO Sequestration Pathway. EPR spectroscopy was used to capture 
NO secretion from whole 4-hydroxytamoxifen treated or untreated Rosa26ERT2 x Cyb5R3Fl/Fl BMDC samples 
following eighteen hours of stimulation in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). Data is 
representative of three experiments. 
 
 
When BMDC from Rosa26ERT2 x Cyb5R3Fl/Fl mice were treated with 4-hydroxytamoxifen, 
harvested, and stimulated for eighteen hours with media alone, LPS, or rIL-33 for NO 
measurement by EPR, the results were unexpected. The knockout of Cyb5R3 resulted in no 
change in NO secretion by DC as compared to the Cyb5R3-expressing DC, regardless of LPS or 
IL-33 stimulation. This demonstrated that Cyb5R3 is not involved in the NO sequestration 
pathway in DC as previously hypothesized. 
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3.7 DELETION OF CYB5R3 FROM CD11C+ BMDC SHIFTS METABOLISM 
TOWARDS GLYCOLYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Deletion of Cyb5R3 from CD11c+ BMDC Causes a Metabolic Shift. Rosa26ERT2 x Cyb5R3Fl/Fl BMDC 
were treated with 4-hydroxytamoxifen or left untreated, CD11c bead purified, and stimulated overnight in media 
alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). Metabolism analysis was performed using a Seahorse XFe96 
Bioanalyzer to obtain A. basal ECAR:OCR, B. basal respiration, and C. ATP turnover of Cyb5R3-expressing and - 
deficient cells. Statistical analysis by Student’s paired t-test. 
 
 
After our results indicated that Cyb5R3 was not functioning as a member of the NO 
sequestration pathway as had been identified in vascular EC [33, 34], we chose to evaluate the 
metabolism of these DC. Cyb5R3 has been suggested to be important to cellular metabolic 
control [44]. Given the importance of the precise modulation of DC metabolism to their 
functionality [2], we evaluated how the deletion of Cyb5R3 impacted DC metabolism at baseline 
and following stimulation with LPS or rIL-33. BMDC were harvested from Rosa26ERT2 x 
Cyb5R3Fl/Fl mice, left untreated or treated with treated with 4-hydroxytamoxifen, CD11c bead 
purified, and stimulated overnight in a 96-well plate with media alone, LPS, or rIL-33 for use the 
following day in a Seahorse XFe96 Bioanalyzer. This was used to measure the extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR) of the DC. From these readings, 
the basal ECAR:OCR ratio, basal respiration, and ATP turnover rates could be determined, 
A   B   C 
23  
which gave insight to the oxidative phosphorylation, glycolysis and fatty acid oxidation 
occurring in the cells. 
Analysis of the ECAR:OCR ratio showed an increase in the excretion of lactic acid 
(following its conversion from pyruvate) over the amount of oxygen consumed across all 
stimulations when Cyb5R3 was absent. This suggested a shift from OXPHOS to glycolysis when 
Cyb5R3 was absent (Figure 9A). 
Analyzing the basal respiration, it was noted there was high oxygen consumption in the 
untreated and IL-33-stimulated Cyb5R3-expressing DC. This was followed by a significant 
decrease in the amount of oxygen consumed after Cyb5R3 knock out. This again suggested a 
shift from OXPHOS to glycolysis when Cyb5R3 was absent and corroborated the conclusions of 
the ECAR:OCR ratio (Figure 9B). 
Analyzing the ATP turnover, high oxygen consumption was again noted in the untreated 
and IL-33-stimulated Cyb5R3-expressing DC, which significantly decreased following Cyb5R3 
knock out. Due to ATP production being the terminal reaction in the electron transport chain in 
OXPHOS, we could link the oxygen consumption rate with the amount of ATP produced as a 
means of determining the DC’s metabolism. Taken together, these three measurements illustrate 
that the deletion of Cyb5R3 from CD11c+ DC causes a metabolic shift from OXPHOS to 
glycolysis. 
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3.8 CD11C+ CYB5R3-DEFICIENT DENDRITIC CELLS SHOW AN INCREASE 
IN STIMULATORY MARKERS AND INFLAMMATORY 
CYTOKINES 
 
 
 
Figure 10. CD11c+ Cyb5R3-Deficient DC show an Increase in Stimulatory Markers and Inflammatory 
Cytokines. Rosa26ERT2 x Cyb5R3Fl/Fl BMDC were treated with 4-hydroxytamoxifen or left untreated and stimulated 
overnight in media alone, LPS (100 ng/ml), or rIL-33 (20 ng/ml). The following day, GolgiPlug was added for 5 
hours to prevent cytokine leakage. These cells were then stained for CD11b, 11c, CD80. CD86, MHC11, and IL- 
12p40 A. y-axis: CD11c, x-axis: IL-12, numbers indicate IL-12hi, CD11c+ population counts B-D. Mean 
fluorescence intensity of CD80, MHCII, and CD86, respectively. Data is representative of two experiments. 
A 
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From the results of the metabolic analysis suggesting that the Cyb5R3-deficient DC utilize 
glycolysis, we next decided it was pertinent to look at the cytokines and stimulatory markers 
produced by these DC. 
Using BMDC harvested from Rosa26ERT2 x Cyb5R3Fl/Fl mice, DC were left untreated or 
 
treated with 4-hydroxytamoxifen, CD11c bead purified, and stimulated overnight with media 
alone, LPS, or rIL-33. The DC were then treated with GolgiPlug for five hours to prevent 
cytokine secretion and stained for CD11b, CD11c, CD80, CD86, MHCII, and IL-12p40. 
Looking at the Cyb5R3-expressing flow plots and gating the cells on CD11c+ DC and IL-12hi, it 
was noted that there was low production of IL-12 in these DC when unstimulated, which 
increased upon LPS stimulation and decreased with IL-33 stimulation. Strikingly, with Cyb5R3 
deficiency, there was an increase in LPS-induced IL-12 production, with a slight increase in IL- 
12 production in unstimulated and IL-33-stimulated DC. Together, this shows that in absence of 
Cyb5R3, DC become more inflammatory. 
Next, looking at the mean fluorescence intensity of the stimulatory surface markers 
CD80, MHCII, and CD86, it was noted that there was a universal increase in DC surface 
expression of each of these markers when Cyb5R3 was knocked out, regardless of stimulation. 
The only exceptions to this were MHCII following LPS-stimulation of Cyb5R3-deficient DC and 
CD86 with no stimulation in Cyb5R3- deficient DC. Taken together, these data suggest that in 
the absence of Cyb5R3, DC become more inflammatory and stimulatory. 
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4.0 DISCUSSION 
 
 
 
4.1 TLR4/ST2 RECEPTOR LIGATION ON DC INDUCES A NITRIC OXIDE 
SEQUESTRATION SYSTEM THAT DOES NOT RELY ON CYB5R3 
 
 
Straub et al. have previously demonstrated that a NO sequestration pathway exists in vascular EC 
and is capable of regulating smooth muscle tone through NO diffusion control [33]. To our 
knowledge, the expression of hemoglobin-α and Cyb5R3 as well as a NO sequestration pathway 
in DC is a novel discovery (Figure 3). Previous literature has shown that DC-produced NO can 
modulate T cell polarization in vitro, with NO synergizing with IL-12 to expand Th1 cells while 
blocking IL-4-mediated Th2 responses [45, 46]. Our data support this idea, following IL-33 
stimulation, and demonstrate that other Th2 cytokines, namely IL-5, are also dampened in the 
presence of NO, with no effect on Th1 polarization following LPS stimulation (Figure 5). 
Though IL-33 is known to be a pleiotropic cytokine [42], its polarization of CD4+ T cells 
towards Th2 cells following DC stimulation with IL-33 and its inability to increase DC NO 
production by iNOS highlight important differences between ST2/TLR4 signaling in the NO 
sequestration system and iNOS signaling pathway (Figures 4 and 5). 
It is interesting that Cyb5R3 does not function in the sequestration pathway as it does in 
EC (Figure 8). It is possible that an as yet undetermined hemoprotein reductase is present and is 
reducing the hemoglobin-α-bound iron group. This may also be due to a redundant reductase 
protein functioning in the place of Cyb5R3. Due to there being four isoforms of Cyb5R in 
humans [47, 48], it is feasible that another could be reducing the Fe3+ group on hemoglobin-α to 
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Fe2+, permitting NO sequestration. 
 
 
4.2 CYB5R3 ACTS AS A REGULATOR OF DENDRITIC CELL STIMULATORY 
CAPACITY TOWARDS CD4+ T CELLS 
 
 
Our results indicate that Cyb5R3, which does not function in the NO sequestration pathway in 
DC (Figure 8), acts as a regulator of DC stimulatory capacity. When Cyb5R3 is present in DC, 
cytokine production levels of IL-5 and IFN-γ by T cells are significantly dampened regardless of 
LPS-DC- or IL-33-DC-stimulation. However, when Cyb5R3-deficient DC are stimulated with 
IL-33 and LPS, robust production of IL-5 and IFN-γ by T cells occurs (Figure 7). 
The idea that Cyb5R3 is important as a signaling regulator for DC is not an unheard-of 
concept. Although it functions as a positive regulatory factor in DC, dendritic cell-specific 
transmembrane protein (DC-STAMP), a multi-membrane protein in the Golgi apparatus of 
mature DC, has been shown to cause BMDC to produce less IL-6, IL-12, tumor necrosis factor 
alpha (TNF-α), and IL-10 and have impaired T cell activation [49]. Therefore, if a positive 
stimulatory regulator such as DC-STAMP exists, it is likely that a negative stimulatory regulator 
such as Cyb5R3 exists, preventing too much T cell activation and an inappropriate immune 
response. 
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4.3 CYB5R3 IS A NEGATIVE REGULATOR OF GLYCOLYSIS AND DENDRITIC 
CELLS SHOW A SHIFTED METABOLIC PROFILE IN ITS ABSENCE 
 
 
As discussed in the last section, Cyb5R3 is important as a negative regulator for DC activation 
(Figure 7), with its absence leading to unchecked T cell stimulation. Our data illustrated a similar 
result following our metabolic and flow cytometry analyses (Figures 9 and 10). Results of the 
basal ECAR:OCR, basal respiration, and ATP turnover between the Cyb5R3-expressing and the 
Cyb5R3-deficient cells suggest that the metabolism of the DC shifts from OXPHOS to  
glycolysis following a loss of Cyb5R3 expression (Figure 9). This is further corroborated by the 
cytokine and surface marker expression analyses. 
Analysis of the Cyb5R3-expressing cells showed that there is low production of IL-12 in 
unstimulated DCs, which increases following LPS stimulation, and decreases with IL-33 
stimulation. However, in the Cyb5R3-deficient DC, an increase in IL-12 production is noticeable 
in unstimulated DC, with a robust increase following LPS stimulation and slight IL-12 
production following IL-33 stimulation. Analysis of the DC stimulatory surface markers CD80, 
MHCII, and CD86, provides further evidence of the importance of Cyb5R3 in the negative 
regulation of glycolysis. In Cyb5R3-expressing cells, the expression of CD80, MHCII, and  
CD86 is minimal in unstimulated and IL-33-stimulated-DC, with an increase in LPS-stimulated 
DC. However, in Cyb5R3-deficient DC, there is an increase in DC surface marker expression, 
regardless of stimulation. These data together demonstrate that in the absence of Cyb5R3, DC 
become more inflammatory. It is known that the activation of DC by pro-inflammatory stimuli 
causes them to undergo a metabolic switch from OXPHOS to glycolysis, leading to the 
upregulation of pro-inflammatory cytokines and stimulatory surface markers [50]. By knocking 
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out Cyb5R3, DC are left without an important internal metabolic regulator, producing the same 
effects seen when Cyb5R3 is present and DC are stimulated with LPS. 
Taken together, this study has elucidated specific proteins integral to DC ability to 
determine CD4+ T cell lineage and improved our understanding of the metabolic shifts that 
occur during TLR4/ST2 ligation. 
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APPENDIX 
 
 
Table 1: Abbreviations 
 
Abbreviation Definition 
Ag antigen 
Alas1 aminolaevulinic acid synthase 1 
AP-1 activator protein 1 
BMDC bone marrow-derived dendritic cells 
CD cluster of differentiation 
Cyb5R3 cytochrome b5 reductase 3 
DAMPs damage-associated molecular patterns 
DC dendritic cells 
DC-STAMP dendritic cell-specific transmembrane protein 
DETA diethylenetriamine 
EC endothelial cells 
ECAR extracellular acidification rate 
ELISAs enzyme-linked immunosorbent assays 
EPR electron paramagnetic resonance spectroscopy 
ER endoplasmic reticulum 
FAD flavin adenine dinucleotide 
FBS fetal bovine serum 
Fe2+ ferrous iron 
Fe3+ ferric iron 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GATA3 GATA-binding protein 3 
Gfi-1 growth factor independent-1 
GM-CSF granulocyte-macrophage colony-stimulating factor 
IFN-γ interferon gamma 
IL interleukin 
IL-1RAcP IL-1 receptor accessory protein 
iNOS inducible nitric oxide synthase 
IRAK IL-1R-associated kinase 
JNK c-Jun N-terminal kinases 
Lcn2 lipocalin 2 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MHC major histocompatibility complex 
MLR mixed lymphocyte reaction 
mRNA messenger RNA 
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MyD88 myeloid differentiation primary response 88 
NADH nicotinamide adenine dinucleotide 
NF-κB nuclear factor kappa B 
NLRs nucleotide-binding oligomerization domain-like receptors 
NO nitric oxide 
NOD nucleotide-binding oligomerization domain 
OCR oxygen consumption rate 
OXPHOS oxidative phosphorylation 
PAMPs pathogen-associated molecular patterns 
PCA principle component analysis 
PRRs pattern recognition receptors 
qRT-PCR quantitative real-time polymerase chain reaction 
RIG-1 retinoic acid-inducible gene 1 
RLRs retinoic acid-inducible gene 1-like receptors 
SEA soluble egg antigen 
SOCS-1 suppressor of cytokine signaling-1 
ST2 IL1RL1/IL-1 receptor like 1 
STAT signal transducer and activator of transcription 
T-bet T-box transcription factor 
TBST tris-buffered saline/Tween 20 
TCR T cell receptor 
Tfh T-follicular helper cell 
Th T helper cell type 
TIR Toll/Interleukin-1 receptor 
TLRs Toll-like receptors 
TNF-α tumor necrosis factor alpha 
TRAF6 tumor necrosis factor receptor-associated factor 6 
Treg T-regulatory cell 
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